AU2003260803A1 - Sustained release pharmaceutical composition - Google Patents
Sustained release pharmaceutical compositionInfo
- Publication number
- AU2003260803A1 AU2003260803A1 AU2003260803A AU2003260803A AU2003260803A1 AU 2003260803 A1 AU2003260803 A1 AU 2003260803A1 AU 2003260803 A AU2003260803 A AU 2003260803A AU 2003260803 A AU2003260803 A AU 2003260803A AU 2003260803 A1 AU2003260803 A1 AU 2003260803A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- sustained release
- release pharmaceutical
- sustained
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN640/MAS/2002 | 2002-08-30 | ||
| IN640CH2002 | 2002-08-30 | ||
| PCT/IB2003/003602 WO2004019901A2 (en) | 2002-08-30 | 2003-08-29 | Sustained release pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003260803A1 true AU2003260803A1 (en) | 2004-03-19 |
| AU2003260803A8 AU2003260803A8 (en) | 2004-03-19 |
Family
ID=34509340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003260803A Abandoned AU2003260803A1 (en) | 2002-08-30 | 2003-08-29 | Sustained release pharmaceutical composition |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003260803A1 (en) |
| WO (1) | WO2004019901A2 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1126826E (en) * | 1998-11-02 | 2008-11-25 | Elan Pharma Int Ltd | Multiparticulate modified release composition of methylphenidate |
| WO2004105728A2 (en) * | 2003-05-27 | 2004-12-09 | Ranbaxy Laboratories Limited | Solid dispersions of cefpodoxime proxetil and processes for their preparation |
| US20060233878A1 (en) * | 2003-09-30 | 2006-10-19 | Lupin Limited | Extended release formulation of beta-lactam antibiotics |
| EA011374B1 (en) * | 2004-01-06 | 2009-02-27 | Панацея Биотек Лимитед | Non-disintegrating oral solid composition of high dose of water soluble drugs |
| GB0400971D0 (en) * | 2004-01-16 | 2004-02-18 | Sandoz Ag | Pharmaceutical compositions |
| EP1681050A1 (en) * | 2005-01-13 | 2006-07-19 | Strides Arcolab Limited | Dispersible sustained release pharmaceutical compositions |
| DE102005019458A1 (en) | 2005-04-25 | 2006-10-26 | Grünenthal GmbH | Composition, useful in the preparation of pellets and the multi-particular-presentation form, comprises cefuroximaxetil and carrageenan of the group of lambda carrageenan, tau carrageenan and kappa carrageenan |
| WO2008057058A1 (en) * | 2006-11-10 | 2008-05-15 | Nobel Ilac Sanayii Ve Ticaret As | Oral pharmaceutical compositions |
| EP2094080B1 (en) * | 2006-11-13 | 2017-06-07 | Basf Se | Utilisation of block copolymers based on vinyl lactames and vinyl acetate as solubilisers |
| CN102028669A (en) * | 2010-10-27 | 2011-04-27 | 北京华禧联合科技发展有限公司 | Slow release preparation of cefcapene pivoxil hydrochloride and preparation method thereof |
| WO2013109202A2 (en) * | 2012-01-18 | 2013-07-25 | Mahmut Bilgic | Pharmaceutical compounds comprising cefetamet |
| US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| US20140274990A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
| EP3043797B1 (en) | 2013-09-09 | 2020-04-08 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| MX2017007287A (en) * | 2014-12-01 | 2017-08-25 | Sun Pharmaceutical Ind Ltd | Extended-release cefpodoxime proxetil composition. |
| CN104434875B (en) * | 2014-12-26 | 2017-08-01 | 华北制药河北华民药业有限责任公司 | A kind of Cefaclor Capsules and preparation method thereof |
| CN107569466A (en) * | 2017-09-17 | 2018-01-12 | 石家庄四药有限公司 | Cefuroxime axetil pharmaceutical composition prepared by a kind of direct compression method |
| CN112023032B (en) * | 2020-09-14 | 2022-03-18 | 广东鼎信医药科技有限公司 | Pharmaceutical composition containing digestive enzyme and preparation method thereof |
| CN113908133B (en) * | 2021-11-29 | 2023-11-03 | 河南省儿童医院郑州儿童医院 | Cefixime sustained release tablet and preparation method thereof |
| WO2025046044A1 (en) * | 2023-09-01 | 2025-03-06 | F. Hoffmann-La Roche Ag | Novel methods for preparing semi-solid compositions and uses thereof |
| CN117243913B (en) * | 2023-10-24 | 2024-09-17 | 国药集团致君(深圳)制药有限公司 | Cefaclor sustained-release composition and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2742989B1 (en) * | 1995-12-29 | 1998-01-23 | Adir | BIOADHESIVE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS |
| AT413647B (en) * | 1998-11-26 | 2006-04-15 | Sandoz Ag | USE OF A COPOLYMERISATE OF 1-VINYL-2-PYRROLIDONE AND VINYL ACETATE FOR THE PREPARATION OF CEFUROXIMAXETIL-SUBJECTED TABLETS |
| WO2001000177A1 (en) * | 1999-06-29 | 2001-01-04 | Micio Pharma Chemical Aktiengesellschaft | Retard formulation of amoxicillin for oral administration |
-
2003
- 2003-08-29 AU AU2003260803A patent/AU2003260803A1/en not_active Abandoned
- 2003-08-29 WO PCT/IB2003/003602 patent/WO2004019901A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004019901A3 (en) | 2005-05-06 |
| AU2003260803A8 (en) | 2004-03-19 |
| WO2004019901A2 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003291103A1 (en) | Pharmaceutical composition | |
| AU2003262059A1 (en) | Sustained release preparation | |
| AU2009201465A1 (en) | Pharmaceutical Compositions with Improved Dissolution | |
| AU2003278393A1 (en) | New use for pharmaceutical composition | |
| EP1469840A4 (en) | Cyclosporin-containing sustained release pharmaceutical composition | |
| AUPR602501A0 (en) | Sustained release pharmaceutical composition | |
| AU2003215334A1 (en) | Inhalable formulations for sustained release | |
| AU2003260803A1 (en) | Sustained release pharmaceutical composition | |
| AU2002337803A1 (en) | Sustained release pharmaceutical compositions | |
| AU2003250372A1 (en) | Pharmaceutical composition | |
| AU2002364468A1 (en) | Solid orally-dispersible pharmaceutical formulation | |
| PL376840A1 (en) | Prolonged release pharmaceutical composition | |
| AU2003241671A1 (en) | Controlled-release drug composition | |
| AU2001248772A1 (en) | Sustained release drug compositions | |
| EP1478353A4 (en) | Sustained release pharmaceutical composition | |
| AU2003267231A1 (en) | Pharmaceutical compositions with improved dissolution | |
| AU2003284460A1 (en) | Medicinal composition | |
| AU2003291642A1 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| AU2003216503A1 (en) | Stable pharmaceutical compositions | |
| AU2003208621A1 (en) | A pharmaceutical composition | |
| AU2003280799A1 (en) | Medicinal composition | |
| AU2003280678A1 (en) | Medicinal composition | |
| AU2003303591A1 (en) | Pharmaceutical compositions with improved dissolution | |
| AUPS188302A0 (en) | Pharmaceutical composition | |
| AU2002236132A1 (en) | Modified release oral pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |